<- Go Home
ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Market Cap
EUR 431.4M
Volume
35.8K
Cash and Equivalents
EUR 222.3M
EBITDA
-EUR 169.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 9.0M
Profit Margin
100.00%
52 Week High
EUR 15.42
52 Week Low
EUR 5.62
Dividend
N/A
Price / Book Value
3.39
Price / Earnings
-2.17
Price / Tangible Book Value
4.22
Enterprise Value
EUR 322.5M
Enterprise Value / EBITDA
-1.91
Operating Income
-EUR 170.2M
Return on Equity
171.46%
Return on Assets
-46.69
Cash and Short Term Investments
EUR 222.3M
Debt
EUR 113.4M
Equity
EUR 126.5M
Revenue
EUR 9.0M
Unlevered FCF
-EUR 82.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium